神經分泌生物科學 NBIX 深 滬
等待開盤 03-26 09:30:00 美东时间
131.13
+3.270
+2.56%
華盛通- 最 高133.045
- 今 開128.98
- 成交量 109.92万股
- 最 低 128.98
- 昨 收 127.86
- 總市值 131.13亿
- 52周最高 160.18
- 市盈率 靜 28.08
- 換手率 1.10%
- 52周最低 84.23
- 委 比 98.77%
- 總股本 10000.00万
- 歷史最高 160.18
- 量 比 0.94
- 振 幅 3.18%
- 歷史最低 5.42
- 每 手 1
- 風險率 13.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多新浪财经ESG：神经分泌生物科学 MSCI（明晟）ESG评级调降至BBB
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
03-24 10:26
美股大行评级 | 潜在涨幅101%！甲骨文获花旗升目标价至320美元，维持"买入"评级
今日重点评级关注：Freedom Capital Markets：维持LifeMD"买入"评级，目标价从8美元升至10美元；Chardan Capital：维持Opus Genetics"买入"评级，目标价从9美元升至11美元
03-13 09:59
JP Morgan Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $177
JP Morgan analyst Anupam Rama maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $176 to $177.
03-13 02:10
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Voyager Therapeutics reported its fourth quarter and full year 2025 financial and operating results, highlighting a transformative year for tau-targeting therapies for Alzheimer's disease (AD) in 2026, with anticipated clinical data for VY1706 and VY7523, entry of IV-delivered neuro gene therapies into the clinic, and advancements in their Voyager NeuroShuttle™ platform. The company ended 2025 with a cash position of $202 million, sufficient to s...
03-09 20:01
BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)
TROY, Mich., March 6, 2026 /PRNewswire/ -- Equifax Inc.'s recent report has investors wondering if the company's stock is fairly valued. Or is it in the buy range? As such, the Editorial Adv...
03-07 06:00
美股大行评级 | 潜在涨幅243.25%！泰利克斯制药获花旗升目标价至22.5美元，维持"买入"评级
今日重点评级关注：花旗：维持Telix Pharmaceuticals"买入"评级，目标价从22美元升至22.5美元；摩根士丹利：维持Vir Biotechnology"超配"评级，目标价从20美元升至24美元
02-25 11:03
Wolfe Research Initiates Coverage On Neurocrine Biosciences with Outperform Rating, Announces Price Target of $160
Wolfe Research analyst Rudy Li initiates coverage on Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform rating and announces Price Target of $160.
02-24 20:14
美股大行评级 | 潜在涨幅1226.53%！RenovoRx获Ascendiant Capital升目标价至13美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从12.5美元升至13美元；Lake Street：维持Insight Molecular"买入"评级，目标价从8美元升至12美元
02-18 16:48
美股大行评级 | AppLovin评级分歧大！高盛等4家下调，韦德布什上调；HubSpot、休曼纳公司、Shopify、Unity、Paycom Software等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从39美元升至47美元；HC Wainwright & Co.：维持Agios制药"买入"评级，目标价从62美元升至65美元
02-13 15:30
Needham Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $185
Needham analyst Ami Fadia maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and lowers the price target from $187 to $185.
02-12 19:13
